Drug Profile
Research programme: CNS disorders therapeutics - National Pharmaceutical/Spencer Pharmaceutical
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Pharmaceutical Corp; Spencer Pharmaceutical
- Developer National Pharmaceuticals Corp; Spencer Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA (PO)
- 01 Nov 2010 Early research in Alzheimer's disease in USA (PO)